On March 24th, 2021, Guests of China Resources Pharmaceutical Group Ltd. were given a tour of Honglin’s production facilities and laboratory for R&D as well as a presentation over Honglin’s prestigious platform of independent-developed extended and controlled release technologies consolidated by core advantages in 4 sectors-R&D, Production skills, Sales enforcement, Service orientation.

During then, the communication was in turns taken to another level by the discussion of contemporary and prospective development of medication business and the further opportunities of strategic alliances in the future, in the anticipation of creating a devotion of offering the best level of product quality and service in the drug market of China.